Vaccinex raises ~$582,500 via private placement of 3.7M shares at $0.156/sh

VACCINEX, INC.

Sold 3,733,973 common shares at $0.156/sh to accredited investors for gross proceeds of ~$582,500.
CEO-controlled entity Vaccinex (Rochester), L.L.C. participated in the placement.
Company granted registration rights for resale of shares within 180 days of closing.
Proceeds to fund pepinemab development and general corporate purposes.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

VACCINEX, INC. entered into Stock Purchase Agreement with the investors named therein (the "Investors") valued at aggregate gross proceeds of approximately $582,500 (effective 2023-09-20).

Action: entry
Agreement: equity purchase
Counterparty: the investors named therein (the "Investors")
Value: aggregate gross proceeds of approximately $582,500
Effective: 2023-09-20

Exact text from the filing

On September 20, 2023, Vaccinex, Inc. (the “Company”) entered into a stock purchase agreement (the “Stock Purchase Agreement”) pursuant to which the Company agreed to issue and sell to the investors named therein (the “Investors”) an aggregate of 3,733,973 shares of common stock, par value $0.0001 per share, of the Company (the “Shares”), at a purchase price of $0.156 per Share (the “Private Placement”).

View on SEC.gov

Browse all material agreements →

VACCINEX, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-240513

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.